Effects of Carnitine Supplement on Dyslipidemia and Anemia in Hemodialysis Patients

Document Type : Original Article (s)

Authors

1 Associate Professor, Kidney Diseases Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

2 Resident,Department of Internal Medicine, School of Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

3 Assistant Professor, Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

4 Research Assistant, Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

5 Resident, Department of Emergency Medicine, Tehran University of Medical Sciences, Tehran, Iran.

6 Research Assistant, Poursina Hakim Research Institute, Isfahan, Iran.

7 Assistant Professor, Department of Emergency Medicine, Sina Hospital,Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Background: Carnitine deficiency is a common condition in patients on maintenance hemodialysis that contributes to dyslipidemia, anemia, and poor general health in these patients. We evaluated the effect of oral L-carnitine supplementation on lipid profile, anemia, and quality of life in hemodialysis patients.Methods: This randomized, double-blinded, placebo-controlled, trial was conducted on dyslipidemic patients on maintenance hemodialysis. Patients in the intervention group (n = 24) received 1 g/d of L-carnitine and the placebo group (27 patients) were similarly taking placebo for 16 weeks. Concentrations of plasma triglycerides, total cholesterol, HDL (High density lipoprotein), LDL (Low density lipoprotein), hemoglobin, erythropoietin dose, and quality of life (QOL or Quality of life, using Short-Form Health Survey) were measured at baseline and 8 and 16 weeks after the beginning of the intervention.Finding: After the intervention, there was a significant decrease in triglyceride (-31.1 ± 38.7 mg/dl, P = 0.001) and a significant increase in HDL (3.7 ± 2.8 mg/dl, P < 0.001) and hemoglobin (0.7 ± 1.7 g/dl, P = 0.037) concentrations in the carnitine groop. Decrease in total cholesterol concentration in the carnitine group was not statistically significant (-6.6 ± 16.0 mg/dl, P = 0.055). No significant change was seen in LDL concentration in any group (P > 0.05). Erythropoietin dose was significantly decreased in both the carnitine (-4750 ± 5772 mg, P = 0.001) and the placebo (-2000 ± 4296 mg, P = 0.033) groups. No improvement was observed in QOL scores or its domains in any group.  Conclusion: In patients on maintenance hemodialysis, oral L-carnitine supplementation has significant beneficial effects on lipid profile. Also, it can increase hemoglobin concentration and subsequently reduce needed erythropoietin dose, but has no considerable effect on quality of life in hemodialysis patients.  

Keywords

References

  1. Hosseinpanah F, Kasraei F, Nassiri AA, Azizi F. High prevalence of chronic kidney disease in Iran: a large population-based study. BMC Public Health 2009; 9: 44.
  2. Shoji T, Nishizawa Y. Chronic kidney disease as a metabolic syndrome with malnutrition--need for strict control of risk factors. Intern Med 2005; 44(3): 179-87.
  3. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008; 28(6): 958-73.
  4. Vaziri ND, Moradi H. Mechanisms of dyslipid-emia of chronic renal failure. Hemodial Int 2006; 10(1): 1-7.
  5. Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V. Carnitine and hemodialysis. Am J Kidney Dis 2003; 41(3 Suppl 1): S116-S122.
  6. Arduini A, Bonomini M, Savica V, Amato A, Zammit V. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 2008; 120(2): 149-56.
  7. Reuter SE, Faull RJ, Evans AM. L-carnitine supplementation in the dialysis population: are Australian patients missing out? Nephrology (Carlton ) 2008; 13(1): 3-16.
  8. Bossola M, Muscaritoli M, Tazza L, Giungi S, Tortorelli A, Rossi FF, et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005; 46(3): 371-86.
  9. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002; 13(3): 708-14.
  10. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol 2004; 4: 26.
  11. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res 2005; 14(3): 875-82.
  12. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48(1): 188-98.
  13. Rathod R, Baig MS, Khandelwal PN, Kulkarni SG, Gade PR, Siddiqui S. Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine
  14. supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. Indian J Med Sci 2006; 60(4): 143-53.
  15. Sloan RS, Kastan B, Rice SI, Sallee CW, Yuenger NJ, Smith B, et al. Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation. Am J Kidney Dis 1998; 32(2): 265-72.
Journal of Isfahan Medical School
Volume 29, Issue 139 - Serial Number 139
March and April 2011
Pages 596-605

Files

History

  • Receive Date: 06 February 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics